The established medical device company is expanding into robotic surgery, a promising new direction. Recent stock performance is mixed, with a slight daily gain but negative returns over the past week, month, and three months. The one-year total shareholder return of 10.3% contrasts with a modest year-to-date share price gain of 1%, suggesting recent momentum has cooled. An analysis assesses the company's valuation following this mixed performance, with some viewing it as a potential long-term hold.